Testing a new saliva test for oral and throat cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the validity of Viome's saliva test for detecting oral and throat cancers, specifically oropharyngeal and oral squamous cell carcinoma. A minimum of 1,000 participants suspected of having these cancers will be enrolled from multiple care centers across the U.S. Clinicians will collect saliva samples using Viome's collection kits, and results will be compared against standard diagnostic methods such as surgical biopsy and clinical assessments. Participants will continue their usual health care while the study assesses the effectiveness of the saliva test.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Signed and dated informed consent prior to any study-specific procedures are performed
* Willing and able to follow the study instructions, as described in the recruitment letter
* Adults (18 years old or older)
* Suspicion of OSCC or OPSCC on clinical presentation by a clinician

Exclusion Criteria:

* Pregnancy
* Use of fertility enhancing medications

Where it's running

• Missouri School of Dentistry & Oral Health
  St Louis, Missouri, United States Recruiting
• Uthsc
  Memphis, Tennessee, United States Recruiting

Study contacts

• Principal investigator: Cristina Julian — Viome
• Study coordinator: Mory Mehrtash
• Email: studies@viome.com
• Phone: 425-300-6933

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Docetaxel and SX-682 in head and neck cancers and prostate cancer

  This trial tests a new drug SX-682 together with docetaxel in adults whose head and neck cancers or prostate cancer have returned or spread.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07667400

• Comparing dual-energy CT and MRI for staging oral and oropharyngeal squamous cell carcinoma

  This will test whether 40 keV dual-energy CT can replace a contrast-enhanced neck and facial MRI for staging adults with oral or oropharyngeal squamous cell carcinoma.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07343271

• Combining sintilimab with reduced chemotherapy for oral cavity cancer treatment

  This study is testing if combining a new immune therapy called sintilimab with fewer chemotherapy sessions can help people with certain types of mouth cancer before they have surgery.

  Recruiting Phase 2 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong · NCT05098119

• Salivary IL-8 and Serum IL-6 as Biomarkers to Distinguish Oral Premalignant Disorders in Smokers and Never-Smokers

  This study tests whether salivary IL-8 and blood IL-6 can help tell apart adults with oral premalignant conditions from those with healthy mouths, and whether smoking influences these markers.

  Recruiting British University In Egypt · Cairo · NCT07915570

• Patient-specific 3D-printed titanium implants for facial reconstruction

  This study tests whether custom-made 3D-printed titanium facial implants can improve reconstruction and appearance for adults with facial bone defects or asymmetry.

  Recruiting Latakia University · Latakia · NCT07654647

• Lowering nodal and primary tumor radiation dose in HPV-positive oropharyngeal cancer

  This phase II study tests whether reducing radiation doses to regions without visible cancer, while keeping the main tumor dose the same, can treat HPV-positive OPSCC with fewer side effects.

  Recruiting Phase 2 University of Cincinnati · Cincinnati, Ohio · NCT07497607

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.